Erik Scalfaro

ORCID

Publication Activity (10 Years)

Years Active: 2018-2024
Publications (10 Years): 5

Top Venues

PharmacoEconomics - open

Drug safety

Novartis Pharma AG

Karolinska Institutet (MSC)

This page only lists publications with an associated author ORCID identifier.

Affiliation History

Novartis Pharma AG Jun 01 2015

Switzerland

Pharmacovigilance Scientist :: Patient Safety

Education History

Karolinska Institutet

Sweden

MSC

University College London - Jun 01 2014

United Kingdom

BSC :: Natural Sciences

Publications

Richard St John Nicholas, Erik Scalfaro, Rachel Dorsey, Zuzanna Angehrn, Judit Banhazi, Roisin Brennan, Nicholas Adlard
ENTIMOS: Decision Support Tool Highlights Potential Impact of Non-intravenous Therapies for Multiple Sclerosis on Patient Care via Clinical Scenario Simulation. PharmacoEconomics - open 8 (5) (2024)
Richard St John Nicholas, Erik Scalfaro, Rachel Dorsey, Zuzanna Angehrn, Judit Banhazi, Roisin Brennan, Nicholas Adlard
ENTIMOS: Decision Support Tool Highlights Potential Impact of Non-intravenous Therapies for Multiple Sclerosis on Patient Care via Clinical Scenario Simulation. PharmacoEconomics - open (2024)
Richard St John Nicholas, Erik Scalfaro, Rachel Dorsey, Zuzanna Angehrn, Judit Banhazi, Roisin Brennan, Nicholas Adlard
ENTIMOS: Decision Support Tool Highlights Potential Impact of Non-intravenous Therapies for Multiple Sclerosis on Patient Care via Clinical Scenario Simulation. PharmacoEconomics - open 8 (5) (2024)
Richard St John Nicholas, Erik Scalfaro, Rachel Dorsey, Zuzanna Angehrn, Judit Banhazi, Roisin Brennan, Nicholas Adlard
ENTIMOS: Decision Support Tool Highlights Potential Impact of Non-intravenous Therapies for Multiple Sclerosis on Patient Care via Clinical Scenario Simulation. PharmacoEconomics - open 8 (5) (2024)
Erik Scalfaro, Henk Johan Streefkerk, Michael Merz, Christoph Meier, David Lewis
Preliminary Results of a Novel Algorithmic Method Aiming to Support Initial Causality Assessment of Routine Pharmacovigilance Case Reports for Medication-Induced Liver Injury: The PV-RUCAM. Drug safety 40 (8) (2018)

Erik Scalfaro.css-eqlu8i{font-size:small;padding-left:4px;}

Publication Activity (10 Years)

Top Topics

Top Venues

Erik Scalfaro